NASDAQ$NXTC
NextCure Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
NextCure prioritized NC410 combo and LNCB74 programs and restructured operations.
NextCure is prioritizing its NC410 combo and LNCB74 programs while seeking partnerships for other assets. The company has restructured operations, reducing the workforce by approximately 37%, and expects current cash reserves to fund operations into the second half of 2026.
- Prioritizing NC410 combo (ovarian and CRC) and LNCB74 (B7-H4 ADC) programs.
- Expanding ovarian and CRC cohorts with data updates expected in 2024 based on early evidence of clinical activity with NC410 combo.
- Planned filing of an IND for LNCB74 by year-end 2024, in collaboration with LegoChem.
- Restructured operations, including a workforce reduction, to better align resources toward prioritized programs.
Headline financials
Revenue & EPS history
NextCure · Revenue · Quarterly
$6.28M
Forward guidance
NextCure expects its existing cash, cash equivalents and marketable securities will enable it to fund operating expenses and capital expenditures into the second half of 2026.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
+0.7%
Avg return
Earnings day
+1.0%
Avg return
5 days after
-1.4%
Avg return
30 days after
36%
10 / 28 earnings
Positive
+34.8%
Q4 2023
Best reaction
-19.8%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -2.9% | +6.6% | -16.0% | |
| Q3 2025 | -8.8% | -5.4% | +25.6% | |
| Q2 2025 | -4.4% | +1.9% | -4.8% | |
| Q2 2024 | -1.2% | +1.9% | -4.8% | |
| Q1 2025 | -7.7% | -20.8% | +2.5% | |
| Q4 2024 | +6.1% | -1.7% | -37.7% | |
| Q3 2024 | -1.5% | +18.0% | -12.6% | |
| Q1 2024 | +11.7% | +15.3% | +12.4% | |
| Q4 2023 | +34.8% | +39.7% | +13.5% | |
| Q3 2023 | +10.3% | +6.5% | +12.1% | |
| Q2 2023 | -2.9% | -2.3% | -18.9% | |
| Q1 2023 | +4.6% | +14.5% | +14.5% | |
| Q4 2022 | -4.5% | -5.1% | -5.7% | |
| Q3 2022 | -19.8% | -31.2% | -42.9% | |
| Q2 2022 | +9.8% | +14.0% | -5.1% | |
| Q1 2022 | -4.5% | -15.1% | +4.8% | |
| Q4 2021 | -1.4% | +0.4% | +2.7% | |
| Q3 2021 | -1.4% | -23.5% | -34.5% | |
| Q2 2021 | +5.8% | +3.2% | +7.5% | |
| Q1 2021 | +3.4% | +5.0% | -1.0% | |
| Q4 2020 | -2.0% | +2.1% | -12.7% | |
| Q3 2020 | -4.3% | +0.9% | +11.0% | |
| Q2 2020 | -1.3% | -3.1% | -14.2% | |
| Q1 2020 | +12.2% | +4.0% | -24.8% | |
| Q4 2019 | -12.3% | +4.0% | +5.2% | |
| Q3 2019 | -3.3% | -7.6% | +31.3% | |
| Q2 2019 | +11.7% | +11.1% | +53.9% | |
| Q1 2019 | -6.8% | -6.3% | +0.5% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro